{"id":"NCT02486939","sponsor":"Coherus Biosciences, Inc.","briefTitle":"A Long Term Safety Extension Study (CHS-0214-05)","officialTitle":"An Open-Label Safety Extension Study (OLSES) Evaluating the Long Term Safety and Durability of Response of CHS-0214 (CHS-0214-05)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07","primaryCompletion":"2017-09","completion":"2017-10","firstPosted":"2015-07-01","resultsPosted":"2018-12-27","lastUpdate":"2018-12-27"},"enrollment":359,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis","Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"CHS-0214","otherNames":[]}],"arms":[{"label":"CHS-0214","type":"EXPERIMENTAL"}],"summary":"An Open-label, Safety Extension Study (OLSES) evaluating the longer-term safety and durability of response of subjects who completed 48 weeks of evaluations in the confirmatory safety and efficacy studies, CHS 0214-02 or CHS-0214-04, evaluating CHS-0214 in patients with rheumatoid arthritis (RA) and plaque psoriasis (PsO), respectively.","primaryOutcome":{"measure":"Durability of Response (Maintenance of an ACR20 Response or Greater), Which Was Measured at Each Visit in Subjects of RA","timeFrame":"48 Weeks","effectByArm":[{"arm":"CHS-0214-02 -RA","deltaMin":117,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":224},"commonTop":["Upper Respiratory Infection","Influenza","Bronchitis","Urinary Tract Infection","Pharyngitis"]}}